Better Biotech Stock: Cassava Sciences vs. Annovis Bio
Investing in pre-product biotech companies often feels like gambling. Financial analysis might not deliver meaningful conclusions for businesses without revenue, and the risks inherent to the drug development process are often discouraging. But buying biotech stocks doesn't need to actually be gambling, provided that you're willing to dive into the details on clinical trials and drug efficacy.
That's exactly what I'll be doing today with Cassava Sciences (NASDAQ: SAVA) and Annovis Bio, (NYSEMKT: ANVS) which are both developing drugs for Alzheimer's disease. Neither company has significant revenue, and it'll likely be years before they do, if ever. Risk-averse investors should probably look elsewhere for biotech stocks. But for the daring, one of the pair is shaping up to be appealing.
Image source: Getty Images.
Source Fool.com
